Fluorescence In Situ Hybridization Market - Forecast(2024 - 2030)

Fluorescence In Situ Hybridization Market Overview

Fluorescence In Situ Hybridization Market size is estimated to reach $1.1 billion by 2027, growing at a CAGR of 6.7% during the forecast period 2022-2027. Fluorescence in Situ Hybridization (FISH) is demarcated as MCT (=molecular cytogenetics technique) which is used to spot explicit genes inside chromosomes in a DNA sample or in intact cells by unswervingly envisioning them with the assistance of a microscope. The elementary purpose of molecular techniques like FISH, In Situ polymerase chain reaction, is DNA and RNA review, and to uncover mutation in genes which leads to maladies like Esophageal Adenocarcinoma. Two independent FISH techniques multicolor FISH (M-FISH) and spectral karyotyping (SKY) are pushing the demand owing to their important diagnostic and research application values. In situ hybridization is contemplated as the best thing since sliced bread as chromosomal anomalies are the preeminent reason for sicknesses like food tube cancer and VCFS (=velocardiofacial syndrome) a blemish in chromosome 22 which cripple body systems’ progress. Ascension in cancer, other health glitches due to genomic mutation, and innumerable chromosomal aberrations are set to drive the growth of the Fluorescence in Situ Hybridization Industry for the period 2022-2027.

Report Coverage:

The report: “Fluorescence in Situ Hybridization Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Fluorescence in Situ Hybridization Market.

By Category: Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA).
By Techniques: Flow FISH, CISH (= Chromogenic in situ hybridization).
By Employment/Application: Cancer, Genetic anomalies, Communicable diseases, and Cell biology.
By End User: Hospitals, academic and research institutes, pharmaceutical companies, research diagnostic laboratories, private research companies.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways:

• Geographically, the North American Fluorescence in Situ Hybridization Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the soaring cases of cancer and contagious viruses. Additionally, substantial investments by the private and government bodies have helped in the growth of the market.
• The substantial concentration on by research and academic institutions in the development of top-notch solutions for diagnosing such illnesses are driving the Fluorescence in Situ Hybridization Market. However, expensive treatments and the prerequisite of an innumerable amount of cash are some of the major factors that are said to condense the growth of the Fluorescence in-Situ Hybridization Market.
• Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Fluorescence in Situ Hybridization Market report.
  
  

  Fluorescence in Situ Hybridization Market- Geography (%) for 2021.

  

Fluorescence in Situ Hybridization Market Segment Analysis - By Employment/Application Type

The Fluorescence in Situ Hybridization Market based on the employment type can be further segmented into Cancer (= esophageal, lungs, kidney, hepatocellular, throat, stomach, pastoral), Genetic anomalies, Communicable diseases, Cell biology. The Cancer segment held the largest share in 2021 owing to the factors such as widespread use in curing cancer due to jaw-dropping precision in maculation of mutations and chromosomal aberrations which are the prominent reason for such anomalies, fluorescence in situ hybridization, offering pinpoint targets for anticancer drugs. Moreover, the US government for example spends close to $210 billion on cancer care.

The Cancer and genetic segment is estimated to be the fastest-growing segment with a CAGR of 7.4% over the period 2022-2027. This growth is owing to a genetic mutation in chromosomes which is leading to the demand for in situ hybridizations, gigantic emphasis on research, and development by numerous public and private players for fabricating state-of-the-art techniques.

Fluorescence in Situ Hybridization Market Segment Analysis - By End User

The Fluorescence in Situ Hybridization Market based on the End User can be further segmented into Hospitals, academic and research institutes, pharmaceutical companies, research diagnostic laboratories, private research companies. The research and diagnostic laboratories segment held the largest share in 2021 owing to the factors such as ascension in the prevalence of various health issues such as cancer around the globe, a surge in demand, and rush hours for research and diagnostic laboratories as maximum hospitals are not fortified with amenities mandatory for such molecular cytogenic techniques.

Moreover, the private research companies’ segment is estimated to be the fastest-growing segment with a CAGR of 7.5% over the forecast period 2022-2027. This growth is owing to the expansion of the following segment, and the rising interest of the big pharma players to not invest in funding indigenous research centers. The benefits weigh for hiring CROs and private companies combine expertise and resources.

Fluorescence in Situ Hybridization Market Segment Analysis - By Geography

The Fluorescence in Situ Hybridization based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 40% of the overall market in 2021. The growth in this segment is owing to the factors such as enlarging cases of genetic anomalies during the birth of children, unhealthy lifestyles of people leading to health problems like obesity, velocardiofacial syndrome, dwindling immunity, and cancer, well-established network of laboratories with world-class facilities.

However, the Asia-Pacific segment is estimated to offer lucrative growth opportunities to marketers over the forecast period 2022-2027. This growth is owing to colossal population, exploding proceeds of pharmaceutical industry of China and India, responsive and supportive government policies, enlarging expenditure on refining health infrastructures such as top-notch laboratories, hospitals, and diagnostic centers. For example, India saw a 139% increment in the budgetary allocation for medical development.

Fluorescence in Situ Hybridization Market Drivers 

A rise in the cases of gene mutation and chromosome abnormalities eventually leading to cancer and other health problems is Projected to Drive Market Growth

Chromosome anomalies and genomic mutations have resulted in the widespread prevalence of cancer among young as well as old age people anywhere in the world due to an expansion in alcohol consumption and cigarette smoking trends, fast food leading to obesity, and strangled immunity. About 20,000 cases of esophageal (=a food tube cancer) cancer were found in the US in starting month of 2021. Therefore, there has been a surge in demand for research and diagnostic laboratories to ramp up their efforts to discover tools and techniques which will outperform the existing ones.

Improving health infrastructure around the globe is Expected to Boost Product Demand

COVID-19 outbreak has caught humans off guard like never before. After the outbreak, there has been an innumerable swell in various transmissible ailments around the globe. Therefore, the healthcare sector is on the top of the governments' priority list which ultimately results in innumerable enlargement in healthcare spending. Developing countries are allocating a surfeit of funds to research and development activities. US healthcare spending is estimated to cross the $6 trillion mark by the year 2028.

Fluorescence in Situ Hybridization Market Challenges

The requirement of massive hard cash for research and the extortionate cost of therapies and lack of skilled professionals is Anticipated to Hamper Market Growth

The price of molecular cytogenetic techniques like fluorescence in situ hybridization is really extortionate which maximum people cannot afford to pay and it could strangle the growth of the same market. Moreover, the preposterous number of riches is essential to set up obligatory infrastructure such as laboratories with required facilities, and in the development of equipment and other apparatuses. On top of that, the field demands highly skilled professionals who possess an extreme amount of knowledge regarding the subject which could hinder the sturdy progress of in situ market.

Fluorescence in Situ Hybridization Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Fluorescence in Situ Hybridization Market. Key companies of this market are-

1. Abnova Corporation
2. Agilent Technologies
3. Horizon Diagnostics
4. Biosearch technologies
5. Creative Biolabs
6. F. Hoffmann-La Roche Ltd.
7. Danaher Corporation
8. BioGenex Laboratories
9. Genemed Biotechnologies Inc
10. PerkinElmer Inc.

Recent Developments/Product Launches:

• On November 14, 2021, a report published by “The Sentinel” claimed that a testing practice NICS (=non-invasive chromosomal screening) can emerge as a game-changer in alleviating fertility problems by IVF (= In Vitro Fertilization) treatments among couples around the world. This process helps to determine whether the embryos have the proper chromosome number. In India, NICS is available only in a few of the metro cities like Mumbai, Kolkata, and Hyderabad. Guwahati is offering this facility to couples undergoing or planning to undergo IVF.
• On November 1, 2021, a study presented in a workshop on CLL (= Chronic Lymphocytic Leukemia) claimed that OGM (=optical genome mapping) can assist in detecting anomalies associated with genes in patients inflicted with leukemia. OGM detected 88% (n = 184) of previously known abnormalities and provided additional structural information in 45% (n = 19) of patients, most of which were associated with microarray copy number alternations (CNAs) or unknown cytogenetic elements reported by chromosome banding analysis (CBA).
• On October 18, 2021, a US-Based biotechnological company “Phase genomics” announced the launch of new RUO a next-generation cytogenetics platform for various applications of sequencing which will lead to extra precision in finding out anomalies in genes through diagnostic techniques. The platform enables rapid, efficient sample processing and does not require culturing of living, dividing cells or high-molecular-weight DNA extraction.

Relevant Links:

In Vitro Diagnostics-Forecast (2022 – 2027)
Report Code: HCR 0553

Tissue Diagnostics Market-Forecast (2022 – 2027)
Report Code: HCR 0564

For more Lifesciences and Healthcare Market reports, please click here